Factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms and the risk of tamoxifen-associated thromboembolism in breast cancer patients.

摘要

Cancer produces a hypercoagulable state which may lead thrombosis. However, the effect of hereditary thrombophilia in cancer patients with thrombosis is still unclear. Some studies have been evaluated the role of factor V Leiden (FVL) mutation on the thrombosis risk in malignancy with conflicting results [1,2]. Cancer therapy can influence the risk of thrombosis as well as type of malignancy, extent of disease. Cytotoxic chemotherapy increases the risk of vascular events in breast cancer patients, especially when combining chemotherapy with hormone therapy [3].